XML 26 R32.htm IDEA: XBRL DOCUMENT
v2.4.1.9

Fair Value Measurements (Details 3) (USD $) In Millions, except Share data, unless otherwise specified | Jul. 30, 2012
--- | ---
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |
Symphony Base Payment in Shares | 13,237,519 lxrx_SymphonyBasePaymentInShares
Symphony Base Payment Obligation | $ 35 lxrx_SymphonyBasePaymentObligation

X
- Definition On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs. Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation. Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates. This represents the 13,237,519 shares of common stock issued to designees of Holdings on July 30, 2012 in satisfaction of the base payment obligation. + References No definition available. + Details
Name: | lxrx_SymphonyBasePaymentInShares
Namespace Prefix: | lxrx_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs. Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation. Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates. This represents the $35 million base payment obligation that was paid in common stock. + References No definition available. + Details
Name: | lxrx_SymphonyBasePaymentObligation
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration